RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted combo shows promise for tough biliary cancers
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (FOLFOX) can shrink tumors or help people with advanced biliary tract cancers live longer. It is for patients whose cancers have specific MAPK gene changes and have already tried one prior trea…
Matched conditions: RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The goal is to find the best dose and see if the combination is safe and can shrink tumors. About 55…
Matched conditions: RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 13:50 UTC